Experimental cell therapy takes on advanced kidney cancer
NCT ID NCT06819293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment called IB-T101 for people with advanced clear cell kidney cancer. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes, which are grown in a lab and then given back to the patient. The study will enroll 12 adults to check if the therapy is safe and if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IB-T101 (a type of immune cell therapy using the patient's own tumor-infiltrating lymphocytes)
What this could lead to
If it works, this could point toward a new treatment option for advanced clear cell kidney cancer that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so it is too soon to know if the treatment is effective or safe. There may be significant side effects from the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji hospital, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••